Eris Lifesciences said that it has formed a joint venture with MJ Biopharm of Mumbai to enter the insulin market.
Eris MJ Biopharm, a 70:30 joint venture with Eris owning 70% of the company, would primarily market and distribute human and analogue insulin, such as Aspart, Glargine, and Lispro, as well as GLP-1 agonists and possibly additional biopharma drugs in India.
MJ will be in charge of the JV’s product development, manufacture, and distribution.